EN
首页 资讯 期刊 导师 问答 求职 发Paper 文献直达 高级搜索 期刊列表
当前位置： X-MOL 学术 › Lipids Health Dis. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Discordant serum lipid parameters
Lipids in Health and Disease ( IF 4.5 ) Pub Date : 2021-02-11 , DOI: 10.1186/s12944-021-01445-5
Ozge Kurmus 1 , Turgay Aslan 1 , Murat Eren 1 , Kursat Akbuga 1 , Liliana Fonseca 1 , Silvia Paredes 1 , Isabel Palma 1
Affiliation  

Dear Editor,

We read with interest the paper by Fonseca et al. entitled “Apolipoprotein B and non-high-density lipoprotein cholesterol reveal a high atherogenicity in individuals with type 2 diabetes and controlled low-density lipoprotein-cholesterol” [1]. The authors state that 22% of the diabetic patients with target low-density lipoprotein cholesterol (LDL-C) level had non-high-density lipoprotein cholesterol (non-HDL-C) level above the target level. Target levels were defined according to the European Society of Cardiology/European Atherosclerosis Society 2016 Guideline for the Management of Dyslipidemia [2].

We previously demonstrated that in 574 consecutive patients who underwent coronary angiography, 15% of them had discordance between LDL-C and non-HDL-C levels [3]; 30% of our study group had type 2 diabetes mellitus (T2DM). In our study, patients with a high difference between non-HDL-C and LDL-C levels were more commonly females, had T2DM and high triglyceride levels [3]. Also, they less commonly received statin therapy [3]. Both the current study [1] and our study [3] measured fasting blood lipids. Measuring apolipoprotein B (Apo B) and oxidized LDL-C level is one of the advantages of the Fonseca et al. study [1]. The authors reported that in addition to non-HDL-C, Apo B and oxidized LDL-C levels were above the recommended range in 25 and 44% of the patients with controlled LDL-C levels, respectively. Non-HDL-C, Apo B and oxidized LDL-C are all potential atherogenic lipid particles [4, 5]. The findings of Fonseca et al. [1] add significant information to previously published data. Comparing the characteristics of patients with non-HDL-C, Apo B and oxidized LDL-C below target with non-HDL-C, Apo B and oxidized LDL-C above target in groups within and above target LDL-C levels separately would be useful for better understanding which patient might have discordant lipid parameters.

Although the size of the study populations and the cut-off values for LDL-C and non-HDL-C to classify patients differ between the current study [1] and our study [3], we both pointed out that sizeable proportion of patients may have low LDL-C and high non-HDL-C levels; T2DM seems to be a risk factor for this pattern. In our study [3], patients with low LDL-C and high non-HDL-C had higher levels of triglycerides than the other patients and high triglyceride levels have been related to discordance of LDL-C and non-HDL-C in previous studies [6, 7]. In the current study [1], there was no significant difference between patients with LDL-C levels within and above target regarding triglyceride levels.

Further studies should be designed to understand the demographic, clinical and laboratory characteristics of patients with discordant lipid parameters. Moreover, the prognosis of cardiovascular disease should be further investigated in follow-up studies in these patients. Despite the low levels of LDL-C, some patients still experience cardiovascular events and patients with low levels of LDL-C but with higher levels of other atherogenic lipid particles may need further evaluation, more aggressive management and close follow-up.

Not applicable.

Apo B:

Apolipoprotein B

LDL-C:

low-density lipoprotein cholesterol

Non-HDL-C:

non-high-density lipoprotein cholesterol

  1. 1.

    Fonseca L, Paredes S, Ramos H, Oliveira JC, Palma I. Apolipoprotein B and non-high-density lipoprotein cholesterol reveal a high atherogenicity in individuals with type 2 diabetes and controlled low-density lipoprotein-cholesterol. Lipids Health Dis. 2020;19:127.

    CAS Article Google Scholar

  2. 2.

    Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37:2999–3058.

    Article Google Scholar

  3. 3.

    Kurmus O, Erkan AF, Ekici B, Aslan T, Eren M. Discordance of low-density lipoprotein Cholestrol and non-high-density lipoprotein Cholestrol and coronary artery disease severity. Arq Bras Cardiol. 2020;114:469–75.

    CAS PubMed PubMed Central Google Scholar

  4. 4.

    Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation. 2005;112:3375–83.

    CAS Article Google Scholar

  5. 5.

    Kattoor AJ, Kanuri SH, Mehta JL. Role of ox-LDL and LOX-1 in Atherogenesis. Curr Med Chem. 2019;26:1693–700.

    CAS Article Google Scholar

  6. 6.

    Kuwabara K, Harada S, Sugiyama D, Kurihara A, Kubota Y, Higashiyama A, et al. Relationship between non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol in the general population. J Atheroscler Thromb. 2016;23:477–90.

    CAS Article Google Scholar

  7. 7.

    Mora S, Buring JE, Ridker PM. Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. Circulation. 2014;129:553–61.

    CAS Article Google Scholar

Download references

Not applicable.

None.

Affiliations

  1. Department of Cardiology, Faculty of Medicine, Ufuk University, Mevlana Bulvari (Konya yolu), No: 86-88, Balgat, Ankara, Turkey

    Ozge Kurmus, Turgay Aslan, Murat Eren & Kursat Akbuga

Authors
  1. Ozge KurmusView author publications

    You can also search for this author in PubMed Google Scholar

  2. Turgay AslanView author publications

    You can also search for this author in PubMed Google Scholar

  3. Murat ErenView author publications

    You can also search for this author in PubMed Google Scholar

  4. Kursat AkbugaView author publications

    You can also search for this author in PubMed Google Scholar

Contributions

OK: major contributor in writing the letter. OK, TA, ME, KA, read and interpreted the article which was previously published in Lipids in Health and Disease journal. All the authors read and approved the final version of the letter.

Corresponding author

Correspondence to Ozge Kurmus.

Ethics approval and consent to participate

Not applicable (This is a “letter to the editor”).

Consent for publication

Not applicable.

Competing interests

None.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

Verify currency and authenticity via CrossMark

Cite this article

Kurmus, O., Aslan, T., Eren, M. et al. Discordant serum lipid parameters. Lipids Health Dis 20, 10 (2021). https://doi.org/10.1186/s12944-021-01445-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12944-021-01445-5

中文翻译：
血脂参数不一致

亲爱的编辑，

我们饶有兴趣地阅读了 Fonseca 等人的论文。题为“载脂蛋白 B 和非高密度脂蛋白胆固醇显示 2 型糖尿病和控制低密度脂蛋白胆固醇的个体具有高致动脉粥样硬化”[1]。作者指出，在目标低密度脂蛋白胆固醇 (LDL-C) 水平的糖尿病患者中，有 22% 的非高密度脂蛋白胆固醇 (non-HDL-C) 水平高于目标水平。目标水平是根据欧洲心脏病学会/欧洲动脉粥样硬化学会 2016 年血脂异常管理指南 [2] 定义的。

我们之前已经证明，在 574 名接受冠状动脉造影的连续患者中，15% 的患者 LDL-C 和非 HDL-C 水平不一致 [3]；我们研究组中 30% 的人患有 2 型糖尿病 (T2DM)。在我们的研究中，非 HDL-C 和 LDL-C 水平差异较大的患者更常见于女性，患有 T2DM 和高甘油三酯水平 [3]。此外，他们较少接受他汀类药物治疗 [3]。目前的研究 [1] 和我们的研究 [3] 都测量了空腹血脂。测量载脂蛋白 B (Apo B) 和氧化的 LDL-C 水平是 Fonseca 等人的优势之一。研究[1]。作者报告说，除了非 HDL-C 外，在 LDL-C 水平得到控制的患者中，分别有 25% 和 44% 的 Apo B 和氧化型 LDL-C 水平高于推荐范围。非 HDL-C，Apo B 和氧化的 LDL-C 都是潜在的致动脉粥样硬化脂质颗粒 [4, 5]。Fonseca 等人的研究结果。[1] 向先前发布的数据添加重要信息。将非 HDL-C、Apo B 和氧化 LDL-C 低于目标的患者的特征与非 HDL-C、Apo B 和氧化 LDL-C 高于目标 LDL-C 水平内和高于目标 LDL-C 水平的组分别进行比较有助于更好地了解哪些患者可能具有不一致的脂质参数。

尽管当前研究 [1] 和我们的研究 [3] 的研究人群规模以及 LDL-C 和非 HDL-C 对患者进行分类的临界值不同，但我们都指出，相当大比例的患者可能有低 LDL-C 和高非 HDL-C 水平；T2DM 似乎是这种模式的风险因素。在我们的研究中 [3]，低 LDL-C 和高非 HDL-C 患者的甘油三酯水平高于其他患者，而高甘油三酯水平与以往的 LDL-C 和非 HDL-C 不一致有关。研究 [6, 7]。在目前的研究 [1] 中，LDL-C 水平在目标范围内和目标以上的患者之间在甘油三酯水平方面没有显着差异。

应设计进一步的研究以了解血脂参数不一致的患者的人口统计学、临床和实验室特征。此外，应在这些患者的随访研究中进一步研究心血管疾病的预后。尽管 LDL-C 水平较低，但一些患者仍会出现心血管事件，而 LDL-C 水平较低但其他致动脉粥样硬化脂质颗粒水平较高的患者可能需要进一步评估、更积极的管理和密切随访。

不适用。

载脂蛋白B：

载脂蛋白B

低密度脂蛋白胆固醇：

低密度脂蛋白胆固醇

非 HDL-C：

非高密度脂蛋白胆固醇

  1. 1.

    Fonseca L、Paredes S、Ramos H、Oliveira JC、Palma I。载脂蛋白 B 和非高密度脂蛋白胆固醇显示 2 型糖尿病和控制低密度脂蛋白胆固醇的个体具有高致动脉粥样硬化性。脂质健康分部。2020；19:127。

    CAS 文章 Google Scholar

  2. 2.

    Catapano AL、Graham I、De Backer G、Wiklund O、Chapman MJ、Drexel H 等。2016 年 ESC/EAS 血脂异常管理指南。Eur Heart J. 2016；37：2999-3058。

    文章 谷歌学术

  3. 3.

    Kurmus O, Erkan AF, Ekici B, Aslan T, Eren M. 低密度脂蛋白胆固醇与非高密度脂蛋白胆固醇的不一致与冠状动脉疾病的严重程度。Arq 胸罩心脏。2020；114：469-75。

    CAS PubMed PubMed Central Google Scholar

  4. 4.

    Pischon T、Girman CJ、Sacks FM、Rifai N、Stampfer MJ、Rimm EB。非高密度脂蛋白胆固醇和载脂蛋白 B 在预测男性冠心病中的作用。循环。2005；112：3375-83。

    CAS 文章 Google Scholar

  5. 5.

    Kattoor AJ、Kanuri SH、Mehta JL。ox-LDL 和 LOX-1 在动脉粥样硬化中的作用。Curr Med Chem。2019；26：1693-700。

    CAS 文章 Google Scholar

  6. 6.

    桑原 K、原田 S、杉山 D、栗原 A、久保田 Y、东山 A 等。一般人群中非高密度脂蛋白胆固醇与低密度脂蛋白胆固醇的关系。J 动脉粥样硬化血栓。2016 年；23：477-90。

    CAS 文章 Google Scholar

  7. 7.

    Mora S、Buring JE、Ridker PM。低密度脂蛋白 (LDL) 胆固醇与替代 LDL 相关测量和未来冠状动脉事件的不一致。循环。2014；129：553-61。

    CAS 文章 Google Scholar

下载参考

不适用。

没有任何。

隶属关系

  1. Ufuk 大学医学院心脏病学系，Mevlana Bulvari (Konya yolu)，编号：86-88，Balgat，安卡拉，土耳其

    Ozge Kurmus、Turgay Aslan、Murat Eren 和 Kursat Akbuga

作者
  1. Ozge Kurmus查看作者出版物

    您也可以在PubMed Google Scholar中搜索此作者 

  2. Turgay Aslan查看作者出版物

    您也可以在PubMed Google Scholar中搜索此作者 

  3. Murat Eren查看作者出版物

    您也可以在PubMed Google Scholar中搜索此作者 

  4. Kursat Akbuga查看作者出版物

    您也可以在PubMed Google Scholar中搜索此作者 

贡献

OK：写这封信的主要贡献者。好的，TA，ME，KA，阅读并解释了之前发表在 Lipids in Health and Disease 杂志上的文章。所有作者都阅读并批准了这封信的最终版本。

通讯作者

与 Ozge Kurmus 的通信。

伦理批准和同意参与

不适用（这是一封“致编辑的信”）。

同意发表

不适用。

利益争夺

没有任何。

出版商说明

Springer Nature 对已出版地图和机构附属机构中的管辖权主张保持中立。

开放获取本文根据知识共享署名 4.0 国际许可协议获得许可，该许可允许以任何媒体或格式使用、共享、改编、分发和复制，只要您适当注明原作者和来源，提供链接到知识共享许可，并指出是否进行了更改。本文中的图像或其他第三方材料包含在文章的知识共享许可中，除非在材料的信用额度中另有说明。如果文章的知识共享许可中未包含材料，并且您的预期用途未得到法律法规的允许或超出允许的用途，则您需要直接从版权所有者处获得许可。要查看此许可证的副本，请访问 http://creativecommons.org/licenses/by/4.0/。

重印和许可

通过 CrossMark 验证货币和真实性

引用这篇文章

Kurmus, O.、Aslan, T.、Eren, M.等。血清脂质参数不一致。脂质健康 Dis 20, 10 (2021)。https://doi.org/10.1186/s12944-021-01445-5

下载引文

  • 收到：

  • 接受：

  • 发表：

  • DOI : https://doi.org/10.1186/s12944-021-01445-5
更新日期：2021-02-11
  点击分享   查看原文
点击收藏
公开下载
阅读更多本刊最新论文 本刊介绍/投稿指南
down
wechat
bug